Progressive Polyradiculopathy in HIV

Back

Overview

While distal symmetric polyneuropathy (DSP) is the most common peripheral nerve disorder seen in patients with HIV, other neuropathic conditions such as polyradiculopathy, acute and chronic inflammatory demyelinating polyneuropathies (IDP), mononeuropathies, mononeuropathy multiplex, and autonomic neuropathy also occur.[1]

Progressive polyradiculopathy typically occurs late in the course of HIV infection, unlike inflammatory demyelinating polyradiculoneuropathies in HIV, which usually occur earlier in the course of disease.[2, 3, 4]  While progressive polyradiculopathy in HIV is uncommon, it is more prevalent in patients with advanced immunosuppression when the CD4 T-cell count is below 50/µL,[5] although it rarely is seen with lesser degrees of immunosuppression.[6]  Given its rare occurrence, incidence rate is unknown. The lumbrosacral region is most often the affected site.

Polyradiculopathy typically results from cytomegalovirus (CMV) infection. In addition to causing mononeuropathy multiplex, in the patient with advanced AIDS, CMV can infect the cauda equina leading to inflammation and destruction of the lumbosacral nerve roots.[7] The most common manifestation of neurological CMV disease in HIV infection is retinitis followed by encephalitis, myelitis, multifocal polyneuropathy, and polyradiculopathy.[8, 9] CMV co-infection of the retina and other sites is common. An idiopathic form of polyradiculopathy exists, which has a better prognosis than the CMV-related form.

Histologically, polyradiculopathy typically features necrosis of nerve roots and endoneurial and epineurial blood vessels, along with marked inflammation. In CMV-associated cases, cytoplasmic and nuclear CMV inclusions may be apparent in Schwann cells and fibroblasts. 

CMV polyradiculopathy is rapidly fatal without treatment. Treatment with foscarnet or ganciclovir may improve or stabilize the condition. Clinical stabilization often occurs after initial worsening during the first 2 weeks of treatment.[3]  Even with treatment, mortality is 22%. In idiopathic polyradiculopathy, spontaneous improvement without treatment is common.[10]

Less common causes of polyradiculopathy in HIV infection include spinal lymphomas, diffuse infiltrative lymphocytosis syndrome, and CNS (central nervous system) opportunistic infections such as tuberculosis meningitis, syphilis, cryptococcosis, herpes simplex virus type 2, varicella-zoster virus, and toxoplasmosis.[6]  

Reactivation of HSV-2 after genital herpes with HIV infection can cause lumbosacral radiculitis.[11] Lumbosacral radiculopathy caused by tuberculous meningitis is due to infection of spinal leptomeninges characterized by granulomatous inflammation. This can compress nerve roots or the cord resulting in radiculopathy.[12] A single case of syphilitic lumbosacral radiculopathy has also been reported.[13]

Idanivir-induced epidural lipomatosis in the lumbar canal causing polyradiculopathy has been described; it resolved with discontinuation of the drug.[14]

Clinical Presentation

Progressive polyradiculopathy presents as a cauda equina syndrome. CMV-related polyradiculopathy is characterized by rapidly progressive ascending numbness, pain, bowel dysfunction, and asymmetric weakness affecting the legs and later occasionally also the arms.[15] These symptoms can develop acutely over days or more subacutely in 1 to 6 weeks. Possibly co-existing CMV-related conditions include retinitis, colitis, and encephalitis. With idiopathic polyradiculopathy, symptoms are more benign and the clinical progression is slower.[16]

Physical examination

The following may be noted in CMV-related polyradiculopathy:

Herpes zoster is characterized by pain and itching followed by rash. Trigeminal and thoracic dermatomes are most commonly affected.[17]

Diagnosis

The presence of CMV polyradiculopathy should be suspected in patients who have progressive lower extremity weakness and decreased or absent reflexes on neurologic examination. (See Clinical Presentation.)

An MRI or contrast CT scan of the spinal cord (or myelogram) should be performed to exclude mass lesions. Nerve root thickening supports the diagnosis of CMV polyradiculopathy.

A lumbar puncture should be done for CSF analysis. A CSF polymorphonuclear pleocytosis with a negative CSF bacterial culture strongly suggests CMV polyradiculopathy in a patient with AIDS who has a CD4 cell count < 50 cells/microL. A positive test for CMV DNA in the CSF supports this diagnosis.[18]

CSF Analysis

Cerebrospinal fluid (CSF) analysis may be useful for differentiation between the various etiologies: the infectious forms (eg, CMV, cryptococcosis, tuberculosis, toxoplasmosis), the idiopathic form, and the neoplastic form (ie, lymphoma). In addition to routine studies, analysis of the CSF for cytology, CMV, Venereal Disease Research Laboratory test (VDRL), and cryptococcal antigen may be performed. The most sensitive techniques, including polymerase chain reaction (PCR), are required to rule out specific treatable infections.

In CMV-related polyradiculopathy, typical CSF findings are as follows:

Pleocytosis usually comprises more than 60% PMNs, but the percentage is sometimes lower. In one study, only 50% of patients had PMN-preponderant pleocytosis. Positive CMV-PCR and elevated protein were the most common CSF findings.[19]

PCR of CSF has a 92% sensitivity and a 94% specificity in CMV-associated progressive polyradiculopathy. CMV culture is positive in only 50% of cases.

CSF findings are different in non-CMV-related progressive polyradiculopathy.

in lymphoma, CSF findings include lymphocytic pleocytosis.

In TB-related cases, CSF findings usually include (but not always) elevated protein, decreased protein and glucose, as well as PMN's often mixed with lymphocytes. Mycobacterial cultures as well as lymph node biopsies may also assist in diagnosis.

In idiopathic cases, CSF findings include:

Other Tests

A complete blood count (CBC) may indicate very low CD4 lymphocyte counts. Blood and urine cultures may indicate CMV and other possible etiologic agents.

MRI with contrast or myelography is useful to exclude cauda equina or spinal cord compressive lesions resulting from lymphoma, syphilis, or toxoplasmosis. Possible findings include the following:

Electromyography and nerve conduction studies may indicate the following:

Treatment and Management

Treatment strategies depend on the etiology.

In idiopathic polyradiculopathy, spontaneous improvement without treatment is common.[10]

For cytomegalovirus (CMV)-associated polyradiculopathy, and other neurologic diseases, prompt initiation of therapy is critical. CMV polyradiculopathy can be fatal within 2 months, making early treatment extremely important.

The initial or induction phase of treatment for patients with CMV neurologic disease depends upon the degree of neurologic impairment as well as the patient’s ability to tolerate the anti-CMV regimen.

For individuals with mild CMV neurologic disease (eg, a patient with CMV polyradiculopathy or mononeuritis multiplex who has mild motor deficits), monotherapy is suggested rather than dual therapy. For patients  capable of taking oral medications, oral valganciclovir 900 mg twice daily is started. For individuals incabable of taking oral medications, intravenous ganciclovir (5 mg /kg every 12 hours) or foscarnet (90 mg/kg every 12 hours) can be used.

Cidofovir is an alternative therapy for the treatment of CMV disease in patients who cannot tolerate any of the other options (ie, ganciclovir, valganciclovir, or foscarnet). Although no controlled trials have evaluated cidofovir for the treatment of CMV neurologic disease, it has been used to treat CMV retinitis. However, the use of cidofovir is limited by its serious, irreversible nephrotoxicity that occurs via dose-dependent proximal tubular cell injury. Because of this toxicity, ganciclovir or foscarnet monotherapy with twice-daily dosing is preferable to using cidofovir.

Because of the risk of fulminant CMV infection in the setting of immune reconstitution inflammatory syndrome (IRIS) after initiation of antiretroviral therapy (ART), a delay of 14 days before ART initiation can be considered.

After the induction anti-CMV treatment regimen has been completed, patients should be transitioned to a maintenance regimen until the CD4 count has increased to ≥ 100 cells/microL for at least six months. Valganciclovir is the typical agent for maintenance therapy.[18]

Induction therapy with ganciclovir and/or foscarnet should be continued until there is significant improvement in the patient’s neurologic symptoms, which typically occurs after several weeks of treatment.[20]

After the patient has improved and ART has been initiated, anti-CMV treatment can be simplified to a maintenance regimen such as valganciclovir monotherapy 900 mg/day. It is suggested to continue valganciclovir until the patient’s viral load is suppressed and the CD4 count has increased to ≥ 100 cells/microL for at least six months. This approach is based upon observational studies regarding the duration of maintenance therapy for patients with CMV retinitis.[21, 22, 23, 24]

Acyclovir inhibits activity of both HSV-1 and HSV-2.

In cases of subacute lumbosacral radiculopathy in immunocompetent individuals, symptoms can resolve spontaneously over weeks. Others have responded to corticosteroids.[25]

Symptomatic treatment for neuropathic pain include agents such as gabapentin, pregabalin, nortriptyline, amitriptyline, lamotrigine, venlafaxine, and duloxetine. Physical therapy is also recommended.

What is progressive polyradiculopathy in HIV infection?Which clinical history findings are characteristic of progressive polyradiculopathy in HIV infection?Which physical findings are characteristic of progressive polyradiculopathy in HIV infection?What is the role of CSF analysis in the workup of progressive polyradiculopathy in HIV infection?Which CSF findings are characteristic of CMV-related progressive polyradiculopathy in HIV infection?Which CSF findings are characteristic of non-CMV-related progressive polyradiculopathy in HIV infection?What is the role of CBC count in the workup of progressive polyradiculopathy in HIV infection?What is the role of MRI in the workup of progressive polyradiculopathy in HIV infection?What is the role of EMG and NCS in the workup of progressive polyradiculopathy in HIV infection?How is progressive polyradiculopathy in HIV infection treated?

Author

Emad R Noor, MBChB, Assistant Professor of Neurology and Clinical Neurophysiology, Hackensack Meridian School of Medicine at Seton Hall University; Attending Neurologist/Clinical Neurophysiologist, NJ Neuroscience Institute at JFK Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Florian P Thomas, MD, PhD, MA, MS, Chair, Neuroscience Institute and Department of Neurology, Director, National MS Society Multiple Sclerosis Center and Hereditary Neuropathy Foundation Center of Excellence, Hackensack University Medical Center; Founding Chair and Professor, Department of Neurology, Hackensack Meridian School of Medicine at Seton Hall University; Professor Emeritus, Department of Neurology, St Louis University School of Medicine; Editor-in-Chief, Journal of Spinal Cord Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD, Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University in St Louis School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Disclosure: Nothing to disclose.

Chief Editor

Niranjan N Singh, MBBS, MD, DM, FAHS, FAANEM, Adjunct Associate Professor of Neurology, University of Missouri-Columbia School of Medicine; Medical Director of St Mary's Stroke Program, SSM Neurosciences Institute, SSM Health

Disclosure: Nothing to disclose.

Additional Contributors

Erik Z Krause, DO, Resident Physician, Department of Neurology, St Louis University School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Mandeep Garewal, MD and Sofia Yahya, MD,to the development and writing of the source article.

References

  1. Robinson-Papp J, Simpson DM. Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve. 2009 Dec. 40 (6):1043-53. [View Abstract]
  2. Bradley WG, Daroff RB, Fenichel GM. Neurological Manifestations of Human Immunodeficiency Virus Infection in Adults. Neurology in Clinical Practice. 2004. 2:1581-1602.
  3. Verma S, Micsa E, Estanislao L, Simpson D. Neuromuscular complications in HIV. Curr Neurol Neurosci Rep. 2004 Jan. 4(1):62-7. [View Abstract]
  4. Kaku M, Simpson DM. HIV neuropathy. Curr Opin HIV AIDS. 2014 Nov. 9(6):521-6. [View Abstract]
  5. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000 Jun. 59(6):1251-60. [View Abstract]
  6. Centner C, Bateman K, Heckmann J. Manifestations of HIV infection in the peripheral nervous system. Lancet Neurology. 2013. 12 (3):295-309.
  7. Miller RG, Storey JR, Greco CM. Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology. 1990 Apr. 40 (4):569-74. [View Abstract]
  8. Sohal A, Riordan A, Mallewa M, Solomon T, Kneen R. Successful treatment of cytomegalovirus polyradiculopathy in a 9-year-old child with congenital human immunodeficiency virus infection. J Child Neurol. 2009 Feb. 24(2):215-8. [View Abstract]
  9. Kameda K, Shirano M, Hadano Y, Kasamatsu Y, Nakamura T, Ota M, et al. Cytomegalovirus polyradiculopathy in three Japanese patients with AIDS. Intern Med. 2015. 54(5):513-8. [View Abstract]
  10. So YT, Olney RK. Acute lumbosacral polyradiculopathy in acquired immunodeficiency syndrome: experience in 23 patients. Ann Neurol. 1994 Jan. 35(1):53-8. [View Abstract]
  11. Chen-Plotkin AS, Christopoulos KA, Venna N. Demyelinating polyneuropathy and herpes simplex lumbosacral radiculitis in a patient with chronic HIV infection. AIDS. 2007. 21 (12):1663-1664.
  12. Masjuan J, Corral I, Fernandez-Ruiz LC. Mycobacterial acute lumbosacral polyradiculopathy as the initial manifestation of AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. 15:175.
  13. Lanska MJ, Lanska DJ, Schmidley JW. Syphilitic polyradiculopathy in an HIV-positive man. Neurology. 1988. 38:1297-301.
  14. Cersosimo MG, Lasala B, Folgar S, Micheli F. Epidural lipomatosis secondary to indinivar in an HIV-positive patient. Clin Neuropharmacol. 2002. 25:51-54.
  15. Anders HJ, Goebel FD. Cytomegalovirus polyradiculopathy in patients with AIDS. Clin Infect Dis. 1998 Aug. 27(2):345-52. [View Abstract]
  16. Robinson-Papp J, Simpson DM. Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve. 2009 Dec. 40(6):1043-53. [View Abstract]
  17. Vafai A, Berger M. Zoster in patients infected with HIV: a review. Am J Med Sci. 2001 Jun. 321(6):372-80. [View Abstract]
  18. Jacobson M. AIDS-related cytomegalovirus neurologic diseases. Up-to-date. April 2019;
  19. Miller RF, Fox JD, Thomas P, et al. Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients. J Neurol Neurosurg Psychiatry. 1996 Nov. 61(5):456-60. [View Abstract]
  20. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med. 1998 May 11. 158 (9):957-69. [View Abstract]
  21. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol. 1998 Dec. 126 (6):817-22. [View Abstract]
  22. Macdonald JC, Karavellas MP, Torriani FJ, Morse LS, Smith IL, Reed JB, et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology. 2000 May. 107 (5):877-81; discussion 881-3. [View Abstract]
  23. Whitcup SM, Fortin E, Lindblad AS, Griffiths P, Metcalf JA, Robinson MR, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999 Nov 3. 282 (17):1633-7. [View Abstract]
  24. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis. 1998 May. 177 (5):1182-7. [View Abstract]
  25. Benatar M, Eastman R. Human Immunodeficiency Virus-Associated Pure Motor Lumbrosacral Polyradiculopathy. JAMA Neurology. July, 2000. 57 (7):1034-1039.
  26. [Guideline] Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10. 58:1-207; quiz CE1-4. [View Abstract]
  27. Douthwaite ST, Taegtmeyer M, Stow R. Cidofovir treatment of HIV-associated cytomegalovirus polyradiculopathy. AIDS. 2006. 20(4):632-4. [View Abstract]
  28. Thongpooswan S, et al. Polyradiculopathy and Gastroparesis due to Cytomegalovirus Infection in AIDS: A Case Report and Review of Literature. The American Journal of Case Reports. November, 2015. 16:801-804.
  29. Eidelberg D, et al. Progressive polyradiculopathy in acquired immune deficiency syndrome. Neurology. 1986. 36 (7):912-6.
  30. Leger JM et al. Lymphoma-induced polyradiculopathy in AIDS: two cases. J Neurol. 1992. 239:132-34.